

Editorial



Digital therapeutics in pain medicine

Ho-Jin Lee^{1,2}

¹Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul, Korea

²Department of Anesthesiology and Pain Medicine, Seoul National University College of Medicine, Seoul, Korea

Received June 3, 2021, Revised June 7, 2021, Accepted June 9, 2021

Handling Editor: Francis S. Nahm

Correspondence

Ho-Jin Lee

Department of Anesthesiology and Pain Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
Tel: +82-2-2072-0039, Fax: +82-2-747-8363, E-mail: zenerdiode03@gmail.com

In this issue of the Korean Journal of Pain, Joo et al. [1] reports a study on the effects of a virtual reality (VR) program on procedure-related pain in patients undergoing fluoroscopy-guided lumbar sympathetic ganglion block. In this study, the VR program provided an additional analgesic effect in combination with local anesthetic infiltration as well as an anxiolytic effect. This non-pharmacologic intervention is expected to be a useful adjunctive treatment for painful interventions, without serious complications.

To the best of my knowledge, the first application of VR technology in pain medicine might be SpiderWorld, a VR program for adjunctive analgesia during burn wound care, employed by Hoffman et al. [2]. Since then, the therapeutic effects of VR have been reported not only in patients with acute pain but also in patients with chronic pain such as fibromyalgia or headache [3]. Currently, several digital healthcare companies are trying to prove the therapeutic effect of VR programs and commercialize them in pain medicine. Firsthand technology Inc., founded by Hoffmann et al., has mainly explored the effects of VR programs, such as SnowWorld, in patients with acute and chronic pain [4]. AppliedVR Inc., another promising company in this field, has explored the efficacy of VR programs

in acute postoperative and chronic pain [5].

However, medical applications of digital technologies are not limited to VR alone. The medical application of software programs or digital devices is being accepted as a new therapeutic modality, called digital therapeutics (DTx), with the accumulation of evidence of their effectiveness in medicine. The Digital Therapeutics Alliance defines DTx as “evidence-based therapeutic interventions driven by high-quality software programs to prevent, manage, or treat a medical disorder or disease” [6]. DTx belongs to contemporary digital healthcare and includes medical devices that focus primarily on the prevention, treatment, and management of diseases. It includes a variety of software programs, such as mobile applications, games, and chatbots, as well as VR. The first DTx application approved by the Food and Drug Administration (FDA) was reSET[®], a cognitive behavioral therapy for substance use disorder using a smartphone application [6]. It was developed by Pear Therapeutics and released in November 2018 in partnership with Sandoz, a division of the Novartis group. Subsequently, reSET-O[®], a smartphone application for opioid use disorder, was released in the market by Pear Therapeutics in December 2018, after obtaining FDA approval [6]. In a recent retrospective claims-based study, the

© This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

© The Korean Pain Society, 2021

Author contributions: Ho-Jin Lee: Writing/manuscript preparation.

use of the reSET-O[®] application was significantly associated with a decrease in medical costs [7]. In Korea, “Nunap vision,” a software-based post-stroke rehabilitation program for visual field defects, was the first DTx application approved by the Ministry of Food and Drug Safety of Korea [8]. Currently, the development of DTx and its validation studies are being conducted in various medical fields [6].

DTx can be useful in various ways in pain medicine. First, DTx can enable collection of real-time pain data, which could provide valuable information to physicians as well as patients. A recent study in Korean fibromyalgia patients evaluated the effects of a real-time pain monitoring system using a wearable device [9]. In particular, rapid advances in wearable device technology will accelerate its implementation [10]. Real-time pain data can be continuously monitored using wearable devices and transferred to wirelessly connected databases [10]. A recent pilot study showed the feasibility of a real-time pain assessment tool using a commercialized smartwatch (Galaxy Gear S3, Samsung Electronics Co, Ltd. Suwon, Korea) in elderly patients [11]. This database could be an important source for big data science in pain medicine [12]. Second, DTx can enable patients to more effectively correct their lifestyle modifications related to chronic pain. The importance of lifestyle factors in the development and sustenance of chronic pain diseases as well as other chronic diseases [13] is often overlooked. Kaia Health, which focuses primarily on musculoskeletal disorders, has reported the effectiveness of their exercise program using smartphone application in patients with chronic low back pain [14]; the usefulness of their application in other musculoskeletal pain diseases is being studied. Third, DTx may play a role in pain education programs. Patient education allows patients to have the right knowledge of their pain, which can motivate them to actively participate in effective treatments. Recently, a pain management education program using a smartphone-based application reduced severity of pain and improved social functioning in adolescents with chronic pain [15]. A recent systematic review reported the beneficial effects of smartphone applications in pain management in an outpatient setting [16].

Although there are a few hurdles, such as regulatory authorization as well as further proof of their effectiveness, it may not be long before these devices can be used in real-world clinical practice, beyond the research area. In pain medicine, DTx are promising treatment option for pain management. Pain physicians should establish academic evidence of these emerging treatment modalities to optimize care for patients with acute and chronic pain and improve their health outcomes.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

FUNDING

No funding to declare.

ORCID

Ho-Jin Lee, <https://orcid.org/0000-0002-7134-5044>

REFERENCES

1. Joo Y, Kim EK, Song HG, Jung H, Park H, Moon JY. Effectiveness of virtual reality immersion on procedure-related pain and anxiety in outpatient pain clinic: an exploratory randomized controlled trial. *Korean J Pain* 2021; 34: 304-14.
2. Hoffman HG, Doctor JN, Patterson DR, Carrougher GJ, Furness TA 3rd. Virtual reality as an adjunctive pain control during burn wound care in adolescent patients. *Pain* 2000; 85: 305-9.
3. Gupta A, Scott K, Dukewich M. Innovative technology using virtual reality in the treatment of pain: does it reduce pain via distraction, or is there more to it? *Pain Med* 2018; 19: 151-9.
4. Firsthand Technology [Internet]. Seattle (WA), San Francisco (CA): Firsthand Technology; 2021. Available at: <https://firsthand.com/vrpr-research/>.
5. AppliedVR [Internet]. Los Angeles (CA): AppliedVR; 2021. Available at: <https://appliedvr.io/research/>.
6. Patel NA, Butte AJ. Characteristics and challenges of the clinical pipeline of digital therapeutics. *NPJ Digit Med* 2020; 3: 159.
7. Velez FF, Colman S, Kauffman L, Ruetsch C, Anastassopoulos K. Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic. *Expert Rev Pharmacoecon Outcomes Res* 2021; 21: 69-76.
8. Choi MJ, Kim H, Nah HW, Kang DW. Digital therapeutics: emerging new therapy for neurologic deficits after stroke. *J Stroke* 2019; 21: 242-58.
9. Lee J, Park SH, Ju JH, Cho JH. Application of a real-time pain monitoring system in Korean fibromyalgia patients: a pilot study. *Int J Rheum Dis* 2019; 22: 934-9.
10. Chen J, Abbod M, Shieh JS. Pain and stress detection using wearable sensors and devices-a review. *Sensors (Basel)* 2021; 21: 1030.

11. Manini TM, Mendoza T, Battula M, Davoudi A, Kheirkhahan M, Young ME, et al. Perception of older adults toward smart-watch technology for assessing pain and related patient-reported outcomes: pilot study. *JMIR Mhealth Uhealth* 2019; 7: e10044.
12. Leem JG. Big data and pain. *Korean J Pain* 2016; 29: 215-6.
13. van Hecke O, Torrance N, Smith BH. Chronic pain epidemiology - where do lifestyle factors fit in? *Br J Pain* 2013; 7: 209-17.
14. Clement I, Lorenz A, Ulm B, Plidschun A, Huber S. Implementing systematically collected user feedback to increase user retention in a mobile app for self-management of low back pain: retrospective cohort study. *JMIR Mhealth Uhealth* 2018; 6: e10422.
15. Shaygan M, Jaber A. The effect of a smartphone-based pain management application on pain intensity and quality of life in adolescents with chronic pain. *Sci Rep* 2021; 11: 6588.
16. Thurnheer SE, Gravestock I, Pichierri G, Steurer J, Burgstaller JM. Benefits of mobile apps in pain management: systematic review. *JMIR Mhealth Uhealth* 2018; 6: e11231.